BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

Ten Adalimumab Biosimilars Now Available in US Market Following Latest FDA Approval

3 months ago

• The FDA has approved ten adalimumab biosimilars, with Simlandi (adalimumab-ryvk) becoming the latest addition in February 2024, expanding treatment options for various autoimmune conditions. • Adalimumab biosimilars come in multiple concentrations and formulations, with some products achieving interchangeable status, offering potential cost savings while maintaining efficacy. • Pharmacists play a crucial role in managing these biosimilars, ensuring proper selection and administration while educating healthcare providers and patients about their safety and benefits.

Semaglutide Shows Promise in Reducing Albuminuria in Non-Diabetic Kidney Disease

7 months ago

• Semaglutide significantly reduced albuminuria in patients with chronic kidney disease (CKD) and obesity but without diabetes, according to the SMART trial. • The study demonstrated a 52.1% placebo-corrected reduction in urine albumin-to-creatinine ratio (UACR) at week 24 with semaglutide treatment. • Semaglutide also led to significant reductions in body weight and waist circumference, suggesting broader metabolic benefits in this patient population. • These findings suggest semaglutide's potential as a therapeutic option for non-diabetic CKD, warranting further investigation into long-term renal protection.